The Multiple Myeloma market holds a diverse range of therapeutic alternatives for treatment, including Proteasome Inhibitors, Immunomodulating Agents, Chemotherapy and many more.

Multiple Myeloma Market Size, Share, Market Research Report

1. Key Insights
2. Report Introduction
3. Multiple Myeloma Market Overview at a Glance
3.1. Market Share (%) Distribution of Multiple Myeloma in 2017: By Country
3.2. Market Share (%) Distribution of Multiple Myeloma in 2030: By Country
3.3. Market Share (%) Distribution of Multiple Myeloma in 2017: By Class
3.4. Market Share (%) Distribution of Multiple Myeloma in 2017: By Class
4. Executive Summary of Multiple Myeloma
4.1. Key Events
5. Epidemiology and Market Forecast Flow
6. Disease Background and Overview
6.1. Introduction
6.2. Multiple Myeloma features
6.2.1. Low blood counts
6.2.2. Bone and calcium problems
6.2.3. Infections
6.2.4. Kidney problems
6.3. Causes of Multiple Myeloma
6.4. Risk factors of Multiple Myeloma
6.5. Signs and Symptoms
6.5.1. Bone Problems
6.5.2. Low blood counts
6.5.3. High blood levels of calcium
6.5.4. Nervous system symptoms
6.5.5. Kidney Problems
6.5.6. Infections
6.6. Pathogenesis of Multiple Myeloma
6.6.1. Molecular mechanisms underlying the progression of multiple myeloma
6.6.2. Molecular pathogenesis of multiple myeloma and its premalignant precursor
6.7. Pathophysiology of Multiple Myeloma
6.8. Patient-related risk factors
6.9. Biomarkers for Multiple Myeloma
6.9.1. Serum M-protein and light chains as biomarkers
6.9.2. Potential proteomic biomarkers
6.9.3. Cytogenetic biomarkers in multiple myeloma
7. Diagnosis of Multiple Myeloma
7.1. Lab tests
7.2. Biopsies
7.3. Imaging tests
7.4. Stages of Multiple Myeloma
8. Treatment
8.1. Drug therapy for Multiple Myeloma
8.1.1. Chemotherapy
8.1.2. Corticosteroids (steroids)
8.1.3. Immunomodulating agents
8.1.4. Proteasome inhibitors
8.1.5. Histone deacetylase (HDAC) inhibitors
8.1.6. Monoclonal antibodies
8.1.7. Nuclear export inhibitor
8.1.8. Using the drugs together or in combination to treat multiple myeloma
8.1.9. Bisphosphonates for bone disease
8.2. Radiation Therapy for Multiple Myeloma
8.3. Surgery for Multiple Myeloma
8.4. Stem Cell Transplant for Multiple Myeloma
8.4.1. Autologous transplants
8.4.2. Allogeneic transplants
8.5. Supportive Treatments for Patients with Multiple Myeloma
8.5.1. Intravenous immunoglobulin (IVIG)
8.5.2. Treatment for low blood cell counts
8.5.3. Plasmapheresis
8.6. Treatment Options for Multiple Myeloma by Stage
8.6.1. Solitary plasmacytomas
8.6.2. Smoldering multiple myeloma
8.6.3. Active (symptomatic) myeloma
8.7. Factors influencing the choice of therapy at relapse
8.8. Treatment Guidelines for Multiple Myeloma
9. Epidemiology and Patient Population
9.1. Key Findings
9.2. Assumptions and Rationale
9.3. Epidemiology Scenario: 8MM
9.3.1. Total Incident Cases of Multiple Myeloma in the 8MM
9.3.2. Total Symptomatic Cases of Multiple Myeloma in the 8MM
9.3.3. Gender-specific cases of Multiple Myeloma in the 8MM
9.3.4. Diagnosed cases of Multiple Myeloma by Age Distribution in the 8MM
9.3.5. Cases of Multiple Myeloma by Treatment Line in the 8MM
9.4. The United States Epidemiology
9.4.1. Total Incident Cases of Multiple Myeloma in the United States
9.4.2. Total Symptomatic Cases of Multiple Myeloma in the United States
9.4.3. Gender-specific cases of Multiple Myeloma in the United States
9.4.4. Diagnosed cases of Multiple Myeloma by Age Distribution in the United States
9.4.5. Cases of Multiple Myeloma by Treatment Line in the United States
9.5. EU-5 Epidemiology
9.6. Germany
9.6.1. Total Incident Cases of Multiple Myeloma in Germany
9.6.2. Total Symptomatic Cases of Multiple Myeloma in Germany
9.6.3. Gender-specific cases of Multiple Myeloma in Germany
9.6.4. Diagnosed cases of Multiple Myeloma by Age Distribution in Germany
9.6.5. Cases of Multiple Myeloma by Treatment Line in Germany
9.7. France
9.7.1. Total Incident Cases of Multiple Myeloma in France
9.7.2. Total Symptomatic Cases of Multiple Myeloma in France
9.7.3. Gender-specific cases of Multiple Myeloma in France
9.7.4. Diagnosed cases of Multiple Myeloma by Age Distribution in France
9.7.5. Cases of Multiple Myeloma by Treatment Line in France
9.8. Italy
9.8.1. Total Incident Cases of Multiple Myeloma in Italy
9.8.2. Total Symptomatic Cases of Multiple Myeloma in Italy
9.8.3. Gender-specific cases of Multiple Myeloma in Italy
9.8.4. Diagnosed cases of Multiple Myeloma by Age Distribution in Italy
9.8.5. Cases of Multiple Myeloma by Treatment Line in Italy
9.9. Spain
9.9.1. Total Incident Cases of Multiple Myeloma in Spain
9.9.2. Total Symptomatic Cases of Multiple Myeloma in Spain
9.9.3. Gender-specific cases of Multiple Myeloma in Spain
9.9.4. Diagnosed cases of Multiple Myeloma by Age Distribution in Spain
9.9.5. Cases of Multiple Myeloma by Treatment Line in Spain
9.10.The United Kingdom
9.10.1. Total Incident Cases of Multiple Myeloma in the United Kingdom
9.10.2. Total Symptomatic Cases of Multiple Myeloma in the United Kingdom
9.10.3. Gender-specific cases of Multiple Myeloma in the United Kingdom
9.10.4. Diagnosed cases of Multiple Myeloma by Age Distribution in the United Kingdom
9.10.5. Cases of Multiple Myeloma by Treatment Line in the United Kingdom
9.11.Japan Epidemiology
9.11.1. Total Incident Cases of Multiple Myeloma in Japan
9.11.2. Total Symptomatic Cases of Multiple Myeloma in Japan
9.11.3. Gender-specific cases of Multiple Myeloma in Japan
9.11.4. Diagnosed cases of Multiple Myeloma by Age Distribution in Japan
9.11.5. Cases of Multiple Myeloma by Treatment Line in Japan
9.12. China Epidemiology
9.12.1. Total Incident Cases of Multiple Myeloma in China
9.12.2. Total Symptomatic Cases of Multiple Myeloma in China
9.12.3. Gender-specific cases of Multiple Myeloma in China
9.12.4. Diagnosed cases of Multiple Myeloma by Age Distribution in China
9.12.5. Cases of Multiple Myeloma by Treatment Line in China
10. Patient Journey
11. Key Endpoints in Multiple Myeloma
12. Marketed Therapies
12.1. Key Cross of Marketed Therapies
12.2. Blenrep (Belantamab Mafodotin /GSK2857916): GlaxoSmithKline
12.2.1. Product Description
12.2.2. Regulatory milestones
12.2.3. Other Developmental Activities
12.2.4. Pivotal Clinical Trial
12.2.5. Clinical Development
12.2.6. Safety and Efficacy
12.3. Abecma (Idecabtagene vicleucel/bb2121/ ide-cel): Bristol-Myers Squibb/Bluebird bio
12.3.1. Product Description
12.3.2. Regulatory Milestones
12.3.3. Other Developmental Activities
12.3.4. Pivotal Clinical Trial
12.3.5. Clinical Development
12.3.6. Safety and Efficacy
12.4. Pepaxto (melflufen/ melphalan flufenamide): Oncopeptides AB
12.4.1. Product Description
12.4.2. Regulatory milestones
12.4.3. Other Developmental Activities
12.4.4. Pivotal Clinical Trial
12.4.5. Clinical Development
12.4.6. Safety and Efficacy
12.5. Farydak (Panobinostat): Secura Bio
12.5.1. Product Description
12.5.2. Regulatory Milestones
12.5.3. Other Developmental Activities
12.5.4. Pivotal Clinical Trials
12.5.5. Ongoing Current Pipeline Activity
12.6. Kyprolis (Carfilzomib): Amgen (Onyx therapeutics)
12.6.1. Product Description
12.6.2. Regulatory Milestones
12.6.3. Other Developmental Activities
12.6.4. Pivotal Clinical Trials
12.6.5. Ongoing Current Pipeline Activity
12.7. Ninlaro (Ixazomib): Takeda Pharmaceutical (Millennium Pharmaceuticals)
12.7.1. Product Description
12.7.2. Regulatory Milestones
12.7.3. Other Developmental Activities
12.7.4. Pivotal Clinical Trials
12.7.5. Ongoing Current Pipeline Activity
12.7.6. Safety and Efficacy
12.8. Sarclisa (Isatuximab): Sanofi
12.8.1. Product Description
12.8.2. Regulatory Milestones
12.8.3. Other Developmental Activities
12.8.4. Pivotal Clinical Trial
12.8.5. Ongoing Clinical Pipeline Activity
12.9. Xpovio (Selinexor; Nexpovio): Karyopharm Therapeutics
12.9.1. Product Description
12.9.2. Regulatory Milestones
12.9.3. Other Developmental Activities
12.9.4. Pivotal Clinical Trial
12.9.5. Ongoing Clinical Pipeline Activity
12.10. Darzalex (Daratumumab): Janssen Biotech
12.10.1. Product Description
12.10.2. Regulatory Milestones
12.10.3. Other Developmental Activities
12.10.4. Pivotal Clinical Trial
12.10.5. Ongoing Pipeline Activity
12.10.6. Safety and Efficacy
12.11. Empliciti (Elotuzumab): Bristol Myers Squibb/AbbVie
12.11.1. Product Description
12.11.2. Regulatory Milestones
12.11.3. Other Developmental Activities
12.11.4. Pivotal Clinical Trials
12.11.5. Ongoing Clinical Pipeline Activity
12.12. Velcade (Bortezomib): Takeda Pharmaceutical/Janssen Pharmaceutical
12.12.1. Product Description
12.12.2. Regulatory Milestones
12.12.3. Other Developmental Activities
12.12.4. Pivotal Clinical Trial
12.13. Pomalyst/Imnovid (Pomalidomide): Bristol-Myers Squibb Company (Celgene)
12.13.1. Product Description
12.13.2. Regulatory Milestones
12.13.3. Other Developmental Activities
12.13.4. Pivotal Clinical Trials
12.13.5. Ongoing Current Pipeline Activity
12.14. Revlimid (Lenalidomide): Celgene (BMS)
12.14.1. Product Description
12.14.2. Regulatory Milestones
12.14.3. Other Developmental Activities
12.14.4. Pivotal Clinical Trials
13. Emerging Therapies
13.1. Iberdomide (CC-220): Bristol-Myers Squibb/Celgene
13.1.1. Product Description
13.1.2. Other Developmental Activities
13.1.3. Clinical Development
13.1.4. Safety and Efficacy
13.2. Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy: RAPA Therapeutics
13.2.1. Product Description
13.2.2. Clinical Development
13.3. Encorafenib in combination with Binimetinib: Pfizer (Array Biopharma)
13.3.1. Product Description
13.3.2. Other developmental activities
13.3.3. Clinical development
13.3.4. Safety and Efficacy
13.4. CLR 131 (131-CLR1404): Cellectar Biosciences
13.4.1. Product description
13.4.2. Other developmental activities
13.4.3. Clinical development
13.4.4. Safety and Efficacy
13.5. Motixafortide (BL-8040): BioLineRx
13.5.1. Product description
13.5.2. Other developmental activities
13.5.3. Clinical development
13.5.4. Safety and Efficacy
13.6. GVAX (GM-CSF) Vaccine: Celgene/Aduro Biotech
13.6.1. Product description
13.6.2. Other developmental activities
13.6.3. Clinical development
13.6.4. Safety and Efficacy
13.7. ECT-001: ExCellThera
13.7.1. Product Description
13.7.2. Other Developmental Activities
13.7.3. Clinical development
13.8. JNJ-7957 (JNJ-64007957, Teclistamab): Janssen Pharmaceutical
13.8.1. Product Description
13.8.2. Other Developmental Activities
13.8.3. Clinical Development
13.8.4. Safety and Efficacy
13.9. PBCAR269A: Precision BioSciences
13.9.1. Product Description
13.9.2. Other Developmental Activities
13.9.3. Clinical Development
13.10. TAK-079: Takeda
13.10.1. Product description
13.10.2. Other Developmental Activities
13.10.3. Clinical Development
13.10.4. Safety and Efficacy
13.11. GBR 1342 (ISB 1342): Glenmark (Ichnos Sciences SA)
13.11.1. Product Description
13.11.2. Other Developmental Activities
13.11.3. Clinical Development
13.12. P-BCMA-101 CAR-T cells: Poseida Therapeutics
13.12.1. Product Description
13.12.2. Other Developmental Activities
13.12.3. Clinical Development
13.12.4. Safety and Efficacy
13.13. MP0250: Molecular Partners AG
13.13.1. Product Description
13.13.2. Other Developmental Activities
13.13.3. Clinical Development
13.13.4. Safety and Efficacy
13.14. Chidamide (Epidaza): Chipscreen Biosciences
13.14.1. Product Description
13.14.2. Other Developmental Activities
13.14.3. Clinical Development
13.15. Venetoclax (ABT-199): AbbVie/Genentech (Roche)
13.15.1. Product Description
13.15.2. Other Developmental Activities
13.15.3. Clinical Development
13.15.4. Safety and Efficacy
13.16. Ciltacabtagene Autoleucel (cilta-cel/ JNJ-4528): Janssen Biotech/Nanjing Legend Biotech
13.16.1. Product Description
13.16.2. Other Developmental Activities
13.16.3. Clinical Development
13.16.4. Safety and Efficacy
13.17. Keytruda (Pembrolizumab): Merck Sharp &amp; Dohme Corp.
13.17.1. Product Description
13.17.2. Other Developmental Activities
13.17.3. Clinical Development
13.17.4. Safety and Efficacy
13.18.Cetrelimab (JNJ-63723283): Janssen
13.18.1. Product Description
13.18.2. Clinical Development
13.18.3. Safety and Efficacy
13.19. REGN5458: Regeneron Pharmaceuticals
13.19.1. Product Description
13.19.2. Other Developmental Activities
13.19.3. Clinical Development
13.19.4. Safety and Efficacy
13.20. Opdivo (Nivolumab): Bristol-Myers Squibb
13.20.1. Product Description
13.20.2. Other Developmental Activities
13.20.3. Clinical Development
13.20.4. Safety and Efficacy
13.21. Descartes-11: Cartesian Therapeutics
13.21.1. Product Description
13.21.2. Other Developmental Activities
13.21.3. Clinical Development
13.22. Imfinzi (Durvalumab): AstraZeneca
13.22.1. Product Description
13.22.2. Other Developmental Activities
13.22.3. Clinical Development
13.22.4. Safety and Efficacy
13.23. Imbruvica (Ibrutinib): Abbvie (Pharmacyclics) and Johnson &amp; Johnson
13.23.1. Product Description
13.23.2. Other Developmental Activities
13.23.3. Clinical Development
13.23.4. Safety and Efficacy
13.24. MOR202 (Felzartamab; TJ-202): MorphoSys AG/I-Mab Biopharma
13.24.1. Product Description
13.24.2. Other Developmental Activities
13.24.3. Clinical Development
13.24.4. Safety and Efficacy
14. Multiple Myeloma: Eight Major Market Analysis
14.1. Key Findings
14.2. Market Outlook
14.3. China Market Outlook
14.4. Eight Major Market Size
14.4.1. Total Market size of Multiple Myeloma in the 8MM
14.4.2. Total Market size of Multiple Myeloma by Therapies in the 8MM
14.5. The United States Market Size
14.5.1. Total Market size of Multiple Myeloma in the United States
14.6. EU-5 Market Size
14.7. Germany
14.7.1. Total Market size of Multiple Myeloma in Germany
14.8. France
14.8.1. Total Market size of Multiple Myeloma in France
14.9. Italy
14.9.1. Total Market size of Multiple Myeloma in Italy
14.10. Spain
14.10.1. Total Market size of Multiple Myeloma in Spain
14.11. The United Kingdom
14.11.1. Total Market size of Multiple Myeloma in the United Kingdom
14.12. Japan Market Size
14.12.1. Total Market size of Multiple Myeloma in Japan
14.13. China Market Size
14.13.1. The total Market size of Multiple Myeloma in China
15.&nbsp;&nbsp;Market Access and Reimbursement of Multiple Myeloma Therapies
15.1. European Market Access Challenges for Relapsed Refractory Multiple Myeloma Triplet Therapies
15.2. IQWIG AND GABA ASSESSMENT
15.3. The Institute for Clinical and Economic Review (ICER)
15.4. NC Medicaid Division of Health Benefits
15.5. Medicare Review on High-Cost CAR T-Cell Therapy
15.6. China Scenario
15.7. Patient Assistance Program
16. Market Drivers
17. Market Barriers
18. SWOT Analysis
19. Unmet Needs
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

Multiple Myeloma- Market Insight, Epidemiology and Market Forecast -2030

DelveInsight's Multiple Myeloma - Market Insights, Epidemiology and Market Forecast - 2030 report provides  the detailed overview of the disease and in depth understanding of historical..